Background: Gamma knife radiosurgery (GKR) can be used for precise targeting of malignant lesions of the CNS when brachytherapy is not an appropriate option. Objectives: This study reports treatment technique, efficacy, and radiation-induced adverse effects in patients with primary and metastatic ocular lesions treated with Leksell GKR. Methods: A retrospective, single-institution review was conducted of 28 patients with primary or metastatic ocular disease, treated from 2000 to 2014. The dose to margin was 17-27 Gy (maximum dose 28-54 Gy). Primary outcomes included overall survival (OS), local control, progression-free survival (PFS), and enucleation. Results: The median age at diagnosis was 70 years, and the median follow-up was 26.4 months. Of the 28 patients, 11 (39%) had metastatic ocular disease, and 17 (61%) were diagnosed with primary ocular melanoma (stage T2a-T4e). The average maximum dose and dose to margin were 41 and 21 Gy, respectively. The mean dose to the optic nerve was 12.6 Gy. The 5-year OS was 46% (95% CI: 23.6-68.4%) for the entire cohort; the 5-year PFS for M0 patients who presented with primary ocular melanoma lesions was 90% (95% CI: 71-100%). Only 1 patient required enucleation after radiation treatment. Conclusion: GKR is an effective option, with acceptable levels of toxicity, in the treatment of primary and metastatic ocular lesions.

Keywords:
Ocular metastases, Choroidal melanoma, Gamma knife radiosurgery
1.
Singh AD, Topham A: Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology 2003;110:956-961.
2.
Klingenstein A, et al: CyberKnife radiosurgery for the treatment of orbital metastases. Technol Cancer Res Treat 2012;11:433-439.
3.
Modorati G, et al: Gamma knife radiosurgery for uveal melanoma: 12 years of experience. Br J Ophthalmol 2009;93:40-44.
4.
Singh AD, Kivela T: The collaborative ocular melanoma study. Ophthalmol Clin North Am 2005;18:129-142, ix.
5.
Schirmer CM, et al: Dose de-escalation with gamma knife radiosurgery in the treatment of choroidal melanoma. Int J Radiat Oncol Biol Phys 2009;75:170-176.
6.
Fakiris AJ, et al: Gamma-knife-based stereotactic radiosurgery for uveal melanoma. Stereotact Funct Neurosurg 2007;85:106-112.
7.
Bellmann C, et al: Stereotactic radiation therapy for malignant choroidal tumors: preliminary, short-term results. Ophthalmology 2000;107:358-365.
8.
Wackernagel W, et al: Local tumour control and eye preservation after gamma-knife radiosurgery of choroidal melanomas. Br J Ophthalmol 2014;98:218-223.
9.
Wackernagel W, et al: Visual acuity after Gamma-Knife radiosurgery of choroidal melanomas. Br J Ophthalmol 2013;97:153-158.
10.
Chan MD, et al: Analysis of visual toxicity after gamma knife radiosurgery for treatment of choroidal melanoma: identification of multiple targets and mechanisms of toxicity. Am J Clin Oncol 2011;34:517-523.
11.
Haas A, et al: Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. Ophthalmology 2002;109:909-913.
12.
Simonova G, et al: Leksell gamma knife treatment of uveal melanoma. J Neurosurg 2002;97(5 suppl):635-639.
13.
Zehetmayer M, et al: Local tumor control and morbidity after one to three fractions of stereotactic external beam irradiation for uveal melanoma. Radiother Oncol 2000;55:135-144.
14.
Gragoudas E, et al: Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol 2002;120:1665-1671.
15.
Damato B, et al: Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys 2005;62:1405-1411.
16.
Egger E, et al: Eye retention after proton beam radiotherapy for uveal melanoma. Int J Radiat Oncol Biol Phys 2003;55:867-880.
17.
Chang MY, McCannel TA: Local treatment failure after globe-conserving therapy for choroidal melanoma. Br J Ophthalmol 2013;97:804-811.
18.
Krema H, et al: Stereotactic radiotherapy for treatment of juxtapapillary choroidal melanoma: 3-year follow-up. Br J Ophthalmol 2009;93:1172-1176.
19.
Goldberg RA, Rootman J, Cline RA: Tumors metastatic to the orbit: a changing picture. Surv Ophthalmol 1990;35:1-24.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.